Prestige BioPharma announced this week that the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application for a proposed trastuzumab biosimilar, HD201. Prestige hopes to eventually sell the product under the name Tuznue.
Prestige BioPharma announced this week that the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application for a proposed trastuzumab biosimilar, HD201, referencing Herceptin. Prestige hopes to eventually sell the product under the name Tuznue.
Lisa S. Park, PhD, chief executive officer of Prestige, said in a statement announcing the application, “We are very pleased that EMA has initiated the review of the HD201 Marketing Authorization Application. It is a major step in our endeavor to become a global player focusing on biosimilars and innovative biologics. Our development approach has proven to be highly efficient with regard to trial performance, demonstrating exceptional similarity, and dossier filing.”
Data published ahead of the 2019 of the American Society of Clinical Oncology meeting highlight the development process for the proposed biosimilar; first, say researchers, analytical comparability in terms of physiochemical and biological properties was assessed for the proposed biosimilar and the EU- and US-licensed reference Herceptin.1
Next, a single-dose phase 1 trial assessed the pharmacokinetic (PK) equivalence between the biosimilar and the EU reference in healthy volunteers. This study showed, say the investigators, that HD201 is safe and well tolerated, and has comparable PK to the EU reference after a single-dose administration.
Following the phase 1 study, a randomized, double-blind, parallel group, multicenter phase 3 study was conducted in comparison with the EU-licensed reference in 500 patients with HER2-positive early breast cancer. According to the investigators, an analysis of a substudy from this phase 3 trial showed comparable results for the biosimilar and the EU reference.
Prestige is also preparing its hopeful launch of the biosimilar; in late 2018, Prestige announced that it had entered into a licensing agreement with Cipla Limited to distribute and market the biosimilar trastuzumab in some emerging markets. Earlier, Prestige announced a deal with Alvogen to commercialize the biosimilar in Central and Eastern Europe.
Reference
1. Hii J, Pivot X, Park LS, et al. HD201: analytical biocomparability and clinical trial progression of trastuzumab [published online May 26, 2019]. J Clin Oncol. doi: 10.1200/JCO.2019.37.15_suppl.e12505.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.